Toxicity and Efficacy Evaluation of Soluble Recombinant Ricin Vaccine

Hyeongseok Yun,Hae Eun Joe,Dong Hyun Song,Young-Jo Song,Sunghyun Hong,Chang-Hwan Kim,Na Young Kim,Gyeung Haeng Hur,Chi Ho Yu
DOI: https://doi.org/10.3390/vaccines12101116
2024-09-29
Vaccines
Abstract:Background: Ricin, a toxin extracted from the seeds of Ricinus communis, is classified as a ribosome-inactivating protein. The A-subunit of ricin shows RNA N-glycosidase activity that cleaves ribosomal RNA (rRNA) and exhibits toxicity by inhibiting protein synthesis and inducing vascular leak syndrome. Methods: In this study, we created a truncated version of the previously developed R51 ricin vaccine (RTA 1-194 D75C Y80C) through in silico analysis. Results: The resulting R51-3 vaccine showed a more-than-six-fold increase in soluble protein expression when compared to R51, with over 85% solubility. In a pilot toxicity test, no toxicity was observed in hematological and biochemical parameters in BALB/c mice and New Zealand white rabbits following five repeated administrations of R51-3. Furthermore, R51-3 successfully protected mice and rabbits from a 20 × LD50 ricin challenge after three intramuscular injections spaced 2 weeks apart. Similarly, monkeys that received three injections of R51-3 survived a 60 μg/kg ricin challenge. Conclusions: These findings support R51-3 as a promising candidate antigen for ricin vaccine development.
immunology,medicine, research & experimental
What problem does this paper attempt to address?